Clinical trials: Heart Failure, Unspecified
Heart Failure
Micronutrient Supplementation in Patients With Heart Failure
There is some evidence to suggest that patients with heart failure may have a reduced dietary intake of vitamins and essential minerals (micronutrients) and that this may worsen the function of the heart.
- Trial name
- MINT-HF (NCT01005303)
- Testing
- Forceval plus 50 micrograms Vitamin D3
- Where
- United Kingdom
- Volunteers
- 79 people
- Sponsor
- Belfast Health and Social Care Trust
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
BIOSTREAM.HF HeartInsight
The main goal is to learn how HeartInsight is used in clinical routine care. HeartInsight is a heart failure monitoring and notification tool within BIOTRONIK's Home Monitoring System.
- Trial name
- NCT05761249
- Testing
- HeartInsight activation
- Where
- 7 sites in Czechia, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Biotronik SE & Co. KG
Heart Failure
Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart failure is a very common cause of hospital admission and there are half a million new cases diagnosed each year in the United States.
- Trial name
- TACC (NCT00599014)
- Where
- 2 sites in United States
- Volunteers
- 335 people
- Sponsor
- Emory University
Heart Failure, Tachycardia, Ventricular
Optisure Lead Post Approval Study
The purpose of this post approval study is to characterize the chronic performance of the SJM Optisure family of HV leads in patients.
- Trial name
- NCT02235545
- Testing
- St. Jude Medical Optisure Lead
- Where
- 60 sites in United States, Belgium and 5 more
- Volunteers
- 1,735 people
- Sponsor
- Abbott Medical Devices
Functional Mitral Regurgitation, Mitral Regurgitation
Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE)
To establish the safety and effectiveness of the Edwards Cardioband System in patients with functional mitral regurgitation (FMR).
- Conditions
- Functional Mitral Regurgitation, Mitral Regurgitation, Mitral Insufficiency
- Trial name
- ACTIVE (NCT03016975)
- Testing
- Edwards Cardioband System, Guideline Directed Medical Therapy
- Where
- 24 sites in United States
- Volunteers
- 12 people
- Sponsor
- Edwards Lifesciences
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy.
- Conditions
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies
- Trial name
- NCT02319005
- Testing
- Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
- Where
- 61 sites in United States, Belgium and 7 more
- Volunteers
- 206 people
- Sponsor
- Alnylam Pharmaceuticals
Congestive Heart Failure
Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
This pilot study will assess the impact of sacubitril/valsartan (trade name Entresto) on the elevated pulmonary artery pressures in patients with heart failure with reduced ejection fraction, measured using a previously implanted…
- Trial name
- PARENT (NCT02788656)
- Testing
- Implantable Hemodynamic Monitor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Brigham and Women's Hospital
Cardiovascular Diseases, Heart Diseases
Pilot Study of Using Copeptin to Predict Response to Tolvaptan
This pilot study will investigate the association between levels of the peptide copeptin and response to tolvaptan, a drug that blocks the action of the water retaining hormone vasopressin.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure
- Trial name
- NCT01346072
- Testing
- tolvaptan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of North Carolina, Chapel Hill
Heart Failure
Advance Cardiac Resynchronization Therapy (CRT) Registry
The intent of this registry is to understand comprehensive clinical care strategies for Cardiac Resynchronization Therapy (CRT) patients especially non-responders in real-world clinical practice.
- Trial name
- NCT01805154
- Testing
- CRT Patients
- Where
- 69 sites in United States, Argentina and 7 more
- Volunteers
- 1,529 people
- Sponsor
- Abbott Medical Devices
Congestive Heart Failure, Diabetes Mellitus
Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Patients with heart failure often have high blood sugar (glucose).
- Trial name
- NCT00812253
- Testing
- Intravenous insulin, Subcutaneous insulin
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Kathleen Dungan
Heart Failure, Coronary Artery Disease
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and…
- Trial name
- COMMANDER HF (NCT01877915)
- Testing
- Rivaroxaban, Standard of care for heart failure and coronary artery disease
- Where
- 562 sites in United States, Argentina and 30 more
- Volunteers
- 5,081 people
- Sponsor
- Janssen Research & Development, LLC
Heart Failure, Congestive
Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure
The SENSE-HF study is a prospective, observational, international multi-center study prospectively evaluating the sensitivity and positive predictive value of the OptiVol Fluid Trends data in predicting Heart Failure related…
- Trial name
- SENSE-HF (NCT00400985)
- Testing
- Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.
- Where
- 2 sites in Belgium, United Kingdom
- Volunteers
- 501 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Systolic Heart Failure, Atrial Fibrillation (Permanent)
Junctional AV Ablation in CRT-D: JAVA-CRT
Cardiac resynchronization therapy (CRT) is a demonstrably effective device intervention for patients with heart failure with reduced ejection fraction and specific indication.
- Trial name
- NCT02946853
- Testing
- Atrioventricular junctional (AVJ) ablation, Cardiac resynchronization therapy - defibrillator
- Where
- 21 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Rochester
Heart Failure
The Cascade Feasibility Pilot (HF) Phase 3
The study proposal is to deploy a wearable solution that predicts physiological perturbation comparable to invasive devices and to perform continuous remote patient monitoring; this will be connected to a structured, cascading…
- Trial name
- NCT04993287
- Testing
- Non-invasive continuous remote monitoring with structured escalation pathway, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Endeavor Health
Heart Failure
Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure
This study will examine whether an intervention with vitamin D or fish oil supplements can reduce the risk of heart failure among adult men and women during a follow up period of up to five years (starting from the time of…
- Trial name
- NCT02271230
- Testing
- Vitamin D and fish oil, Fish oil (EPA/DHA) alone, Vitamin D alone
- Where
- United States
- Volunteers
- 25,871 people
- Sponsor
- Brigham and Women's Hospital
Ischemic and Non-ischemic Cardiomyopathy
OptiVol for Precision Medical Management of Heart Failure
This clinical study is designed to show that a multidisciplinary team following a pre-specified standard of care medication decision model based on data from an implanted cardioverter device will increase the rate of change in…
- Trial name
- (OPTIMED-HF) (NCT04206501)
- Testing
- Medtronic ICD with Opti Vol-Monitor
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Rochester
Healthy Volunteer
Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of omecamtiv mecarbil in healthy volunteers in Japan.
- Trial name
- NCT02601001
- Testing
- Omecamtiv mecarbil
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Cytokinetics
Heart Failure, Pulmonary Disease, Chronic Obstructive
Advancing Symptom Alleviation With Palliative Treatment
Chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD), and interstitial lung disease (i.e., pulmonary fibrosis) are common serious illnesses.
- Conditions
- Heart Failure, Pulmonary Disease, Chronic Obstructive, Emphysema, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- ADAPT (NCT02713347)
- Testing
- ADAPT Intervention
- Where
- 2 sites in United States
- Volunteers
- 306 people
- Sponsor
- VA Office of Research and Development
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
This is a randomized study of ambrisentan that will last 16 weeks. The study will include patients with diastolic heart failure and pulmonary hypertension. Patients will be randomized (1:1) to ambrisentan or placebo.
- Trial name
- NCT00840463
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center